Table 1_Avoiding the cost of complacency: barriers and solutions to ending the HIV epidemic in Europe.docx

This study explores the implications of failing to meet these targets by quantifying the associated costs and identifying pathways to get back on track.</p>Methods<p>We adopted a mixed-methods approach across eight European countries.

Targeted literature reviews estimated annual and lifetime HIV costs, identified barriers and solutions, and assessed evidence on long-acting injectables (LAIs). Epidemiological data from UNAIDS and ECDC informed projections of HIV prevalence and diagnoses to 2030 under three scenarios. Semi-structured stakeholder consultations validated and expanded the evidence base, and an expert roundtable prioritized solutions and evaluated LAIs' potential impact.</p>Results<p>If current trends persist, over 98,000 new HIV diagnoses are projected between 2025–2030, adding more than €4 billion in healthcare costs and nearly €36 billion in lifetime costs.